Convertibles Calendar: T-Mobile to price $870 million deal; Envestnet on tap

December 9

T-MOBILE US INC.:

• $870 million of mandatory convertible preferreds

• Greenshoe of $130 million

• Registered, off the shelf

• Talked to yield 3%-3.5%, up 25%-30%

• Joint bookrunners Goldman Sachs & Co., Morgan Stanley & Co. LLC and Citigroup Global Markets Inc.

• Co-managers Barclays, Credit Suisse Securities (USA) LLC, Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC

• Proceeds for general corporate purposes, including capital investment and acquisition of additional spectrum

• Bellevue, Wash.-based wireless messaging and data services company

• Nasdaq: TMUS

ENVESTNET INC.:

• $125 million of convertible senior notes

• Talked 1.5%-2%, up 30%-35%

• Maturity Dec. 1, 2019

• $18.75 million greenshoe

• Registered, off the shelf

• Non-callable for life

• Net share settlement

• Joint bookrunners Nicolaus & Co. Inc., Credit Suisse Securities (USA) LLC and BMO Capital Markets Corp.

• Co-managers Sandler O’Neill + Partners, LP, Sterne Agee & Leach Inc. and William Blair & Co.

• Proceeds for general corporate purposes, including selective strategic investments through acquisitions

• Chicago-based specialty wealth management software and services provider

• NYSE: ENV

December 10

FIAT CHRYSLER AUTOMOBILES NV:

• $2.5 billion of mandatory convertibles

• Greenshoe of $375 million

• In conjunction with IPO of Fiat SpA

• Concurrent 87 million shares of common stock

• Registered

• Pricing Dec. 10

• Talked to yield 7.125%-7.875%, up 17.5%-22.5%

• Joint bookrunners Goldman Sachs & Co., J.P. Morgan Securities LLC, Barclays, UBS Securities LLC, Citigroup Global Markets Inc., BofA Merrill Lynch and Morgan Stanley & Co. LLC

• Proceeds for general corporate purposes

• London-based Italian and U.S. automaker

• Nasdaq: FCAU

IGI LABORATORIES INC.:

• $125 million of convertible senior notes

• $18.75 million greenshoe

• Talked 3.25%-3.75%, up 25%-30%

• Five year bonds

• Rule 144A

• Non-callable for three years, then provisionally callable at 150% price hurdle

• Takeover and dividend protection

• Joint bookrunners Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC

• Proceeds for general corporate purposes, including selective capital expenditures and acquisitions and strategic transactions.

• Hillside, N.J.-based pharmaceutical company

• NYSE: IG

On The Horizon

INOTEK PHARMACEUTICALS CORP.:

• Convertible senior notes

• Maturity 2019

• Concurrent initial public offering of common stock

• Registered

• Non-callable for life

• Takeover and dividend protection

• Joint bookrunners Cowen & Co. LLC, Piper Jaffray & Co., Canaccord Genuity Inc. and Nomura Securities International Inc.

• Proceeds to fund the continued development of its pharmaceutical candidates and for other general corporate purposes, including repayment of borrowings under and the termination of existing notes payable agreements

• Beverly, Mass.-based development stage pharmaceutical company

• Proposed Nasdaq listing: ITEK

CARNIVAL GROUP INTERNATIONAL HOLDING LTD.:

• Unsecured senior convertible bonds

• Bookrunner Deutsche Bank AG, Hong Kong Branch

• Regulation S

• Concurrent equity swap with Deutsche Bank AG, London Branch as equity swap counterparty

• Proceeds to fund existing and new projects; entry into the equity swap; and for working capital and other general corporate purposes

• Bermuda-based investment holding company engaged in leisure and consumption businesses

• Hong Kong: 00996

SB FINANCIAL GROUP INC.:

• $10 million to $15 million of convertible preferred shares

• Managed by Keefe Bruyette & Woods Inc.

• Registered

• Can be converted to common stock after five years

• Proceeds to redeem a portion of the company’s junior subordinated debentures underlying the trust preferred securities issued by the company’s RST I subsidiary and for general corporate purposes

• Defiance, Ohio-based community banking, mortgage banking, wealth management services company

• Nasdaq: SBFG

PLATFORM SPECIALTY PRODUCTS CORP.:

• Convertible securities as part of a funding package of cash, convertibles, debt and equity

• Proceeds to fund $3.51 billion acquisition of Arysta LifeScience Ltd., a Tokyo-based provider of agrochemical and biological products

• Barclays, Credit Suisse Securities (USA) LLC, Nomura Securities International LLC and UBS AG acted as M&A advisers and have committed financing for the acquisition

• Anticipated closing in first quarter 2015

• Miami-based specialty chemicals company

• NYSE: PAH

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.